Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Cellectis SA ( (CLLS) ) has provided an announcement.
Cellectis S.A. has convened a combined general meeting of shareholders for June 25, 2026, at the Biopark auditorium in Paris, where investors will review the 2025 annual and consolidated financial statements, which reflect significant losses, and vote on the allocation of results and carried-forward losses. The ordinary agenda also includes renewing four directors’ mandates and authorizing a share buyback program, decisions that will shape corporate governance and capital management.
On the extraordinary agenda, shareholders will be asked to approve multiple delegations of authority enabling the board to carry out a wide range of capital increases, many with preferential subscription rights waived in favor of targeted investor categories in the health, biotech and financial sectors. The meeting will also consider amendments to governance rules, including the chairman’s age limit and bylaw updates, plus new employee share-based incentive plans and a company savings plan, underscoring Cellectis’s drive to secure flexible financing options and align staff interests as it navigates ongoing losses and seeks strategic funding.
The most recent analyst rating on (CLLS) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Cellectis SA stock, see the CLLS Stock Forecast page.
Spark’s Take on CLLS Stock
According to Spark, TipRanks’ AI Analyst, CLLS is a Neutral.
The score is primarily constrained by weak financial performance—large ongoing losses, meaningful cash burn, and rising leverage. Technical indicators are moderately supportive with neutral momentum and prices holding around key moving averages, but valuation remains pressured due to negative earnings and no dividend data.
To see Spark’s full report on CLLS stock, click here.
More about Cellectis SA
Cellectis S.A. is a France-based biotechnology company focused on gene-editing technologies, particularly allogeneic CAR-T cell therapies for cancer and other serious diseases. The company targets the global healthcare and life sciences markets, leveraging its expertise in genome engineering to develop innovative therapeutic platforms in partnership with pharmaceutical and biotech players.
Average Trading Volume: 40,585
Technical Sentiment Signal: Hold
Current Market Cap: $267.6M
Learn more about CLLS stock on TipRanks’ Stock Analysis page.